Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, recently presented data from a preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of leptomeningeal metastases (LM), and presented plans for a Phase 1 clinical trial of 186RNL also in LM. The data and upcoming trial plans were presented in two electronic posters (ePosters) at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), which was held virtually from August 19 to 20, 2021.

To read more please visit:

Plus Therapeutics Presents Data from Preclinical Study of rhenium-186 Nonoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming phase 1 Clinical Trial-PLUS

Source: PLUS; THERAPETICS